Elekta AB Unsponsored ADR Class B ( (EKTAY) ) has released its Q2 earnings. Here is a breakdown of the information Elekta AB Unsponsored ADR Class B presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Elekta AB Unsponsored ADR Class B is a leading company in the medical technology sector, specializing in precision radiation therapy solutions for cancer treatment. The company is known for its innovative products and services that enhance patient care worldwide.
In its latest earnings report for the second quarter of the fiscal year 2025/26, Elekta announced a strategic reset aimed at improving operational execution and profitability. The company reported a 1% increase in net sales at constant exchange rates, driven primarily by strong performance in Europe, despite a 6% decline in reported sales in SEK.
Key financial highlights include an improved adjusted gross margin of 37.9%, up from 35.7% the previous year, and a net income increase to SEK 229 million. The company also initiated a new operating model to enhance product development and commercial execution, which is expected to result in annual cost savings of at least SEK 500 million starting in the first quarter of 2026/27. Additionally, Elekta conducted an order review, leading to a cancellation of SEK 2,197 million to strengthen its order backlog.
Looking ahead, Elekta’s management remains optimistic about the company’s growth prospects, expecting net sales to grow year-over-year in constant currency terms. While challenges such as foreign exchange rates and tariffs persist, the company is focused on regaining market share through innovation and a customer-first approach.